Form 4 - Statement of changes in beneficial ownership of securities:
SEC Accession No. 0000950170-25-074289
Filing Date
2025-05-19
Accepted
2025-05-19 16:01:06
Documents
1
Period of Report
2025-05-19

Document Format Files

Seq Description Document Type Size
1 4 ownership.html 4  
1 4 ownership.xml 4 2898
  Complete submission text file 0000950170-25-074289.txt   4354
Mailing Address C/O UROVANT SCIENCES, INC. 5281 CALIFORNIA AVENUE, SUITE 100 IRVINE CA 92617
Business Address
Katkin Keith (Reporting) CIK: 0001314596 (see all company filings)

Type: 4 | Act: 34 | File No.: 001-37708 | Film No.: 25963747

Mailing Address 730 THIRD AVENUE 9TH FLOOR NEW YORK NY 10017
Business Address 730 THIRD AVENUE 9TH FLOOR NEW YORK NY 10017 781-419-1400
Syndax Pharmaceuticals Inc (Issuer) CIK: 0001395937 (see all company filings)

EIN.: 320162505 | State of Incorp.: DE | Fiscal Year End: 1231
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)